BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Trump administration plan to reduce access to some student loans angers nurses, health care groups - 2Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- 3Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- 4Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid.
- 5Qatar, Ireland accuse Israel of using chemical weapons on Palestinians, demand watchdog probe use
- Blood pressure drug recalled for possible cross-contamination
- In a scientific first, biologists recorded a wild wolf potentially using tools
- People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- Find Unexpected, yet invaluable treasure Excursion Rentals
- Many European nations want Israel to cancel 19 new settlement plans
- BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet
- Get To Be familiar with The Historical backdrop Of Western Medication
